Advanced search×

Managing biotechnology in a network-model health plan: a U.S. private payer perspective.

Health Aff (Millwood) 25(5):1347-52 (2006) PMID 16966732

Emerging biotechnology poses challenges to payers, including access, coverage, reimbursement, patient selection, and affordability. Premera Blue Cross, a private regional health plan, developed an integrated cross-functional approach to managing biologics, built around a robust formulary process that is fast, flexible, fair, and transparent to stakeholders. Results are monitored by cost and use reporting from merged pharmacy and medical claims. Utilization management and case management strategies will integrate with specialty pharmacy programs to improve outcomes and cost-effectiveness. Creative approaches to provider reimbursement can align providers' incentives with those of the plan. Redesign of member benefits can also encourage appropriate use of biotechnology.

DOI: 10.1377/hlthaff.25.5.1347
Version: za2963e q8za5 q8zb7 q8zcb q8zd0 q8ze5 q8zf7 q8zg8

Similar articles you may find interesting…

  1. Determination of free acidic and alkaline residues of protein via moving reaction boundary titration in microdevice electrophoresis.

    Analyst (2013) PMID 23671907

    We developed the concepts of moving reaction boundary (MRB) and MRB titration, relevant MRB titration theory, and the method of microdevice electrophoresis for the determination of free acidic and alkaline residues of protein. In the MRB titration, the boundary was created with acid or alkali and ta...
  2. A Randomized Controlled Trial comparing the efficacy of low-dose amitriptyline, amitriptyline with pindolol and surrogate placebo in the tre...

    Rhinology 51(2):143-53 (2013) PMID 23671895

    Patients often present to otolaryngologists with chronic facial pain, presumed to be of sinus origin despite normal nasal endoscopy and sinus CT. This pain has increasingly been recognized as being of neurological origin with one of the commonest underlying causes being mid-facial se...
  3. The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.

    J Med Econ (2013) PMID 23647483

    At 2 years, treatment with onabotulinumtoxinA was associated with an increase in costs of £1,367 and an increase in QALYs of 0.1 compared to placebo, resulting in an incremental cost-effectiveness ratio (ICER) of £15,028. Treatment with onabotulinumtoxinA reduced headache days by an estimated 38 d...